Cost-effectiveness of FDG-PET

Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Oncologic Patients Neoplasms

Age range

13 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cancer

Exclusion criteria

Other malignancy
Uncontrolled Diabetes
Pregnancy

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Collaborators

Netherlands: Ministry of Health, Welfare and Sports

Registry information

Official study title

Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Important dates

Study start: 2005
Primary completion: 2010
Study completion: 2011
First posted: Sep 21, 2011
Registry last updated: Sep 21, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed